The estimated Net Worth of David R.W. Jayne is at least $490 Mille dollars as of 21 May 2024. David Jayne owns over 4,946 units of Aurinia Pharmaceuticals Inc stock worth over $289,697 and over the last 3 years he sold AUPH stock worth over $28,390. In addition, he makes $171,717 as Independent Director at Aurinia Pharmaceuticals Inc.
David has made over 2 trades of the Aurinia Pharmaceuticals Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently he sold 4,946 units of AUPH stock worth $28,390 on 21 May 2024.
The largest trade he's ever made was exercising 8,733 units of Aurinia Pharmaceuticals Inc stock on 18 May 2023 worth over $57,026. On average, David trades about 3,420 units every 92 days since 2021. As of 21 May 2024 he still owns at least 44,364 units of Aurinia Pharmaceuticals Inc stock.
You can see the complete history of David Jayne stock trades at the bottom of the page.
Dr. David R.W Jayne serves as Independent Director of the Company. Dr. David Jayne is Professor of Clinical Autoimmunity in the Department of Medicine at the University of Cambridge, UK. Dr. Jayne received his MBBChir in Surgery and Medicine from Cambridge University, Cambridge, England. He received postgraduate training at several London hospitals and Harvard University. He is a fellow of the Royal Colleges of Physicians of London and Edinburgh, and the Academy of Medical Science. He is a certified nephrologist and an Honorary Consultant Physician at Addenbrooke’s Hospital, Cambridge UK. Dr. Jayne is a medical advisor to UK, U.S. and EU regulatory bodies, patient groups and professional organizations. He has published more than 400 peer-reviewed journal articles, book chapters and reviews. He was elected the first President of the European Vasculitis Society in 2011 and is a member of the ERA-EDTA immunopathology working group and he co-chairs the EULAR/ERA-EDTA task force on lupus nephritis. Dr. Jayne’s research includes investigator-initiated international trials and the introduction of newer therapies in vasculitis and SLE with collaborators on five continents.
As the Independent Director of Aurinia Pharmaceuticals Inc, the total compensation of David Jayne at Aurinia Pharmaceuticals Inc is $171,717. There are 15 executives at Aurinia Pharmaceuticals Inc getting paid more, with Peter Greenleaf having the highest compensation of $1,678,600.
David Jayne is 63, he's been the Independent Director of Aurinia Pharmaceuticals Inc since 2015. There are 4 older and 10 younger executives at Aurinia Pharmaceuticals Inc. The oldest executive at Aurinia Pharmaceuticals Inc is George Milne, 76, who is the Independent Chairman of the Board.
David's mailing address filed with the SEC is #140, 14315 - 118 AVENUE, , EDMONTON, A0, T5L 4S6.
Over the last 4 years, insiders at Aurinia Pharmaceuticals Inc have traded over $22,019,765 worth of Aurinia Pharmaceuticals Inc stock and bought 107,125 units worth $893,295 . The most active insiders traders include Timothy P Walbert, Michael R Hayden e Michael Robert Martin. On average, Aurinia Pharmaceuticals Inc executives and independent directors trade stock every 18 days with the average trade being worth of $193,451. The most recent stock trade was executed by Scott Michael Habig on 6 August 2024, trading 18,249 units of AUPH stock currently worth $96,902.
aurinia pharmaceuticals is a biotechnology company located in 5120-75 street, edmonton, canada.
Aurinia Pharmaceuticals Inc executives and other stock owners filed with the SEC include: